CytoSorbents Corporation · NASDAQ:CTSO

CytoSorbents — Investor Presentation (July 2023)

33 slides from CytoSorbents's investor presentation, July 2023

  1. Slide 1: Investor Presentation July 2023

    HELPING TO TREAT LIFE-THREATENING CONDITIONS IN THE ICU AND CARDIAC SURGERY AROUND THE WORLD NASDAQ: CTSO Investor Presentation July 2023

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiaries CytoSorbents Medical, Inc and CytoSorbents Europe GmbH that are not historical facts are forward- looking statements and are subject to risks and uncertainties that could cause act

  3. Slide 3: CytoSorbents

    CytoSorbents Leading the Prevention or Treatment of Life-Threatening Inflammation and other Deadly Conditions in the ICU and Cardiac Surgery using CytoSorb® Blood Purification 3

  4. Slide 4: CytoSorbents At a Glance

    CytoSorbents At a Glance (NASDAQ: CTSO) • U.S.-based international medical device company commercializing our E.U. approved CytoSorb® blood purification cartridge in 75 countries worldwide • $34.7M in 2022 total revenue • $29.4M in 2022 product sales, 70% product gross margins • $20.7M in cash (3/31

  5. Slide 5: Marketed Products and Product Pipeline

    Marketed Products and Product Pipeline Internal development supplemented by strong government support with ~$48M in grants, contracts, other non-dilutive funds awarded to date for our technology from DARPA, NIH, NHLBI, U.S. Army, U.S. Air Force, HHS, and others Sepsis, Critical Removal of Care, High

  6. Slide 6: What does CytoSorb do and How does it work?

    What does CytoSorb do and How does it work?? 6

  7. Slide 7: The CytoSorb adsorber

    The CytoSorb adsorber The underlying blood purification technology is based on biocompatible, highly porous polymer beads that act like tiny sponges to remove harmful substances from blood • Massive surface area: 7 football fields in a single cartridge • 19 issued U.S. patents and multiple patents i

  8. Slide 8: Expanding the Dimension of Blood Purification

    Expanding the Dimension of Blood Purification CytoSorb is fundamentally different from, but complementary to, dialysis technology, removing a broad range of dissimilar toxins that dialysis does not remove well CytoSorb works like the liver Dialysis works like the kidney with some kidney function Lar

  9. Slide 9: CytoSorb is "Plug and Play" Compatible

    CytoSorb is “Plug and Play” Compatible Compatible with Existing Blood Pump Infrastructure In Hospitals Today Dialysis or CRRT ECMO (Continuous Renal Replacement Therapy) (Extracorporeal Membrane Oxygenation) Hemoperfusion CPB (Standalone Treatment) (Cardiopulmonary Bypass) 9

  10. Slide 10: Targets Deadly Conditions That Afflict Millions of People

    Targets Deadly Conditions That Afflict Millions of People Critical Care Cardiothoracic Surgery Removes the “fuel to the fire” of massive Reduces inflammation and blood thinners, uncontrolled inflammation that is often targeting reduction in complications of cardiac associated with organ failure and

  11. Slide 11: Example of how CytoSorb is Saving Lives Today

    Example of how CytoSorb is Saving Lives Today “Enhanced Lung Rest” with CytoSorb and ECMO under FDA EUA achieved 74% 90-day survival in 100 COVID patients with refractory lung failure from 5 major U.S. centers (CTC Registry) 30 day 90 day survival survival 86% 74% ECMO Alone 90-Day survival: 53% ELS

  12. Slide 12: Riding Many Macro Trends in Healthcare

    Riding Many Macro Trends in Healthcare Aging Population is Getting Older The Use of Blood Thinners Millions worldwide are on blood thinners to reduce risk of stroke and heart attack >1 billion over 60 Chronic Liver Disease Endocarditis Afflicts 1 in 11 worldwide 12

  13. Slide 13: Unlocking Value with Strategic Partners

    Unlocking Value with Strategic Partners Synergies with Attractive Growing Body of Partner Platforms Economics Clinical Evidence Acute Care & ECMO Cardiovascular & ECMO Organ Transplant Universal Plasma - Indicates current CTSO partner CytoSorbents Confidential 13

  14. Slide 14: What is the Company's Business model and Financial performance?

    What is the Company’s Business model and Financial performance? 14

  15. Slide 15: CytoSorbents Has a Strong Hybrid Sales Model

    CytoSorbents Has a Strong Hybrid Sales Model 75 Countries Worldwide and >200,000 devices utilized Critical Care and Cardiac Surgery Direct Sales Distributor and Partner Sales Direct sales in 15 countries: Distributor and Partner sales in >60 other countries Germany, Austria, Switzerland, Belgium, En

  16. Slide 16: CytoSorb Commercialization Focus

    CytoSorb Commercialization Focus By Market By Geography Other Critical Care – 17% • ARDS • Reversal of Shock 38% Distributor / Partner • Trauma 17% Critical Care 67% • Acute Liver / Pancreatic • Austria • Many Others 19% Other Direct • Switzerland Sepsis Cardiac Cardiac Surgery – 33% • 13 other and

  17. Slide 17: CytoSorb Is a High Margin "Razorblade"

    CytoSorb Is a High Margin “Razorblade” • High margin “razorblade” fully compatible with existing installed base of “razor” blood pumps: Dialysis, CRRT, and ECMO machines (ICU), and heart-lung machines (OR) • Blended historic gross margins are 80+%, driven by volume production from our current manufa

  18. Slide 18: Total Quarterly Product Sales

    Total Quarterly Product Sales Product Sales $12.0 Core Non-COVID-19 Product Sales COVID-19 Sales $2.5 $1.7 $10.0 $2.7 $1.8 $1.7 $2.4 $9.7 $1.1 $9.0 $7.9 $0.0 $7.7 $0.3 $7.6 $0.0 $8.0 $0.0 $8.3 $1.6 $8.0 $7.8 $7.5 $6.5 $0.0 $ IN MILLONS $7.3 $7.1 $6.6 $6.5 $6.0 $5.9 $5.7 $5.5 $5.2 $5.1 $4.6 $4.4 $4.0

  19. Slide 19: New Manufacturing Facility Now Fully Operational

    New Manufacturing Facility Now Fully Operational • Relocated to new Princeton, NJ headquarters with our new ISO 13485-certified manufacturing facility that increases manufacturing capacity by 5x to $350-400M in annual sales • CytoSorb and ECOS-300CY are currently being commercially manufactured on t

  20. Slide 20: What are the catalysts to create value?

    What are the catalysts to create value? Grow CytoSorb sales Get DrugSorb-ATR approved in U.S. and Canada – the second engine of growth 20

  21. Slide 21: Grow CytoSorb Sales

    #1 Grow CytoSorb Sales a1 CytoSorhents.

  22. Slide 22: Markets are Improving Post-COVID

    Markets are Improving Post-COVID • Seeing a firming of our markets worldwide, including the core Germany market, related to our efforts last year with sequential growth in Q1 2023 product sales and 8% quarterly growth year over year • Continued strong positive support from customers, where the feedb

  23. Slide 23: Important Recent Developments

    Important Recent Developments • New, expanded global marketing agreement with FMC, the market leader in dialysis worldwide with headquarters and a stronghold market in Germany, to make CytoSorb the “featured technology” for cytokine, bilirubin, and myoglobin removal on their platform Germany • Prefe

  24. Slide 24: Get DrugSorb-ATR Approved in the U.S. and Canada – the Second Engine of Growth

    #2 Get DrugSorb-ATR Approved in the U.S. and Canada – the Second Engine of Growth 24

  25. Slide 25: EU Approval to Remove Brilinta and Xarelto "Blood Thinners"

    EU Approval to Remove Brilinta and Xarelto “Blood Thinners” During Cardiothoracic Surgery CytoSorb has received E.U. approval to remove two well-known blockbuster “blood thinners” during cardiothoracic surgery, used in millions of patients to reduce risk of stroke and heart attacks. Last week, hemoa

  26. Slide 26: Risk of Bleeding Is High in CABG Patients on Brilinta

    Risk of Bleeding Is High in CABG Patients on Brilinta In the Brilinta (ticagrelor) registration PLATO (PLAeleT inhibition and patient Outcomes) trial, 1584 patients underwent CABG surgery, randomized between those who received either ticagrelor or clopidogrel. Those patients (%) with life-threatenin

  27. Slide 27: By Removing Drug, CytoSorb Reduces Bleeding Complications

    By Removing Drug, CytoSorb Reduces Bleeding Complications In a separate analysis done in the U.K., this has translated into a projected cost savings to the hospital of approximately $5,000 per patient, including the cost of CytoSorb • Hassan K, et al. Ann Thor Surg. 2019; 1:45-51. • Javanbakht, M, e

  28. Slide 28: Targeting U.S. & Canada Marketing Approval

    Targeting U.S. & Canada Marketing Approval • We seek U.S. FDA and Health Canada marketing approval of DrugSorb™-ATR to remove the blood thinners, Brilinta®, and Xarelto® and Eliquis® ($16.7B in 2021 sales) during open heart surgery, to reduce potentially fatal bleeding complications • We were awarde

  29. Slide 29: United States TAM for Ticagrelor Removal

    United States TAM for Ticagrelor Removal 50,000 patients on ticagrelor needing emergent/urgent open heart surgery annually in US X $5,000 per device $250M Initial U.S. Total Addressable Market Ticagrelor market share expected to grow • DrugSorb-ATR would make ticagrelor the only reversible platelet

  30. Slide 30: Addressable U.S. Market For Current and Potential Future Indications

    Addressable U.S. Market For Current and Potential Future Indications for Antithrombotic Removal by DrugSorb-ATR Eliquis®, Xarelto® and Brilinta® $2.0B All surgery Eliquis®, Xarelto® and Brilinta® $1.0B Cardiac surgery Brilinta® Cardiac surgery $500M (Future) Brilinta® Cardiac surgery $250M (Today) 3

  31. Slide 31: Today: CytoSorb Drives our Growth

    Today: CytoSorb Drives our Growth • CytoSorb forms the Company’s foundation • E.U. approved and sold around the world • Generated ~$200M in sales since launch • High margin razorblade business model with industry top-tier 80+% blended product gross margins • Strong validation by customers, partners,

  32. Slide 32: Soon: CytoSorb & DrugSorb-ATR = Dual Growth Engines

    Soon: CytoSorb & = Dual Growth Engines • We are racing to the finish of STAR-T, where we are rapidly nearing the completion of the study, expected in August 2023, with top-line data later this year • Should STAR-T be successful and DrugSorb-ATR achieves U.S. FDA and Health Canada regulatory approval

  33. Slide 33: Helping to Treat Life-Threatening Conditions in the ICU and Cardiac Surgery

    HELPING TO TREAT LIFE-THREATENING CONDITIONS IN THE ICU AND CARDIAC SURGERY AROUND THE WORLD Dr. Phillip Chan Kathleen Bloch Chief Executive Officer Interim Chief Financial Officer pchan@cytosorbents.com kbloch@cytosorbents.com

CytoSorbents — Investor Presentation (July 2023) on 6ix